Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDX-060 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MDX-060 plus standard of care | EXPERIMENTAL | MDX-060 in combination with gemcitabine |
| Standard of care | ACTIVE_COMPARATOR | Gemcitabine |
| Name | Type | Description |
|---|---|---|
| MDX-060 | DRUG | anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg |
Inclusion Criteria: * Diagnosis of Hodgkin's disease \[HD\] (excluding HIV-associated HD) * Patients must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained...
MDX-060 is an investigational small molecule being studied for the treatment of Hodgkin's Disease. It is being developed by Bristol-Myers Squibb Company (BMY) and has completed a Phase 2 clinical trial in patients with relapsed or refractory Hodgkin's Disease.
MDX-060 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research on this investigational oncology drug for Hodgkin's Disease.
MDX-060 is in Phase 2 clinical development. It has completed one Phase 2 trial in patients with relapsed or refractory Hodgkin's Disease. The drug is investigational and has not been approved by regulatory authorities.
MDX-060 has one completed clinical trial, NCT00284804, titled "A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease." This Phase 2 study enrolled 74 participants in the United States and was active-controlled.
MDX-060 is not FDA approved. It is an investigational drug currently in clinical development for Hodgkin's Disease. The drug has completed a Phase 2 trial, but approval status has not been established.